Table 1 Main characteristics of BCR-ABL... | American Society of Hematology

Table 1

Main characteristics of BCR-ABL and JAK2V617F mutated patients

Patient	Sex	Age, y	JAK2V617F burden, %	CML duration at sampling, months	CML phase at sampling	Features of Ph negative MPN	At CML diagnosis					Clinical features
Patient	Sex	Age, y	JAK2V617F burden, %	CML duration at sampling, months	CML phase at sampling	Features of Ph negative MPN	Karyotype	Transcript	WBC, ×10^9/L	HB, g/dL	PLT, ×10^9/L	Clinical features
1	F	82	61	9	CP	previous PV	46,XX,t(9;22)(q34;q11)	b3a2	46	11.8	462	Previously diagnosed with PV, in treatment with HU at time of diagnosis of CML; she failed to achieve CCyR with imatinib and dasatinib as first and second line therapy
2	F	58	9	75	CP	none	46,XX,t(9;22)(q34;q11)	b3a2	136,6	11.1	383	Patient initially treated with HU and then shifted to imatinib; she obtained CCyR, but at time of sampling for JAK2 assessment presented loss of MMR and a karyotype with trisomy of ch.8
3	F	67	39	80	CP	none	n/a	nd	29,9	11.6	355	Patient treated with imatinib as first line, shifted to dasatinib as second line due to loss of response. At time of sampling for JAK2 assessment presented loss of MMR
4	M	52	15	140	CP	Persistent thrombocytosis	n/a	b2a2	8,5	14.9	773	With imatinib therapy he obtained MMR, but thrombocytosis persists
5	M	71	19	38	CP	none	n/a	e8a3	n/a	n/a	n/a	Patient initially treated with HU and then shifted to imatinib; he obtained CCyR and MMR
6	F	52	25	35	CP	none	46,XX,t(9;22)(q34;q11)	b3a2	147,7	9.9	2250	Patient initially treated with HU and then shifted to imatinib; she obtained CCyR and MMR
7	F	71	13	75	CP	none	46,XX,t(9;22)(q34;q11) [15/15]	b2a2	24,57	13.7	200	Patient treated with imatinib as first line, shifted to dasatinib as second line due to failing to achieve MMR. At time of sampling for JAK2 assessment she was in CCyR
8	F	69	15	102	CP	none	46,XX,t(9;22)(q34;q11) [10/10]	b3a2	13,26	13.8	302	Patient treated with imatinib plus pegilated interferon, followed by imatibib alone. At time of sampling for JAK2 assessment was out of therapy, in MMR

Patient	Sex	Age, y	JAK2V617F burden, %	CML duration at sampling, months	CML phase at sampling	Features of Ph negative MPN	At CML diagnosis					Clinical features
Patient	Sex	Age, y	JAK2V617F burden, %	CML duration at sampling, months	CML phase at sampling	Features of Ph negative MPN	Karyotype	Transcript	WBC, ×10^9/L	HB, g/dL	PLT, ×10^9/L	Clinical features
1	F	82	61	9	CP	previous PV	46,XX,t(9;22)(q34;q11)	b3a2	46	11.8	462	Previously diagnosed with PV, in treatment with HU at time of diagnosis of CML; she failed to achieve CCyR with imatinib and dasatinib as first and second line therapy
2	F	58	9	75	CP	none	46,XX,t(9;22)(q34;q11)	b3a2	136,6	11.1	383	Patient initially treated with HU and then shifted to imatinib; she obtained CCyR, but at time of sampling for JAK2 assessment presented loss of MMR and a karyotype with trisomy of ch.8
3	F	67	39	80	CP	none	n/a	nd	29,9	11.6	355	Patient treated with imatinib as first line, shifted to dasatinib as second line due to loss of response. At time of sampling for JAK2 assessment presented loss of MMR
4	M	52	15	140	CP	Persistent thrombocytosis	n/a	b2a2	8,5	14.9	773	With imatinib therapy he obtained MMR, but thrombocytosis persists
5	M	71	19	38	CP	none	n/a	e8a3	n/a	n/a	n/a	Patient initially treated with HU and then shifted to imatinib; he obtained CCyR and MMR
6	F	52	25	35	CP	none	46,XX,t(9;22)(q34;q11)	b3a2	147,7	9.9	2250	Patient initially treated with HU and then shifted to imatinib; she obtained CCyR and MMR
7	F	71	13	75	CP	none	46,XX,t(9;22)(q34;q11) [15/15]	b2a2	24,57	13.7	200	Patient treated with imatinib as first line, shifted to dasatinib as second line due to failing to achieve MMR. At time of sampling for JAK2 assessment she was in CCyR
8	F	69	15	102	CP	none	46,XX,t(9;22)(q34;q11) [10/10]	b3a2	13,26	13.8	302	Patient treated with imatinib plus pegilated interferon, followed by imatibib alone. At time of sampling for JAK2 assessment was out of therapy, in MMR